On the public citation graph
Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects
0 signed · 157 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/eji.200636508openalex-snapshot
Immunisation with recombinant modified vaccinia virus Ankara expressing HIV‐1 gag in HIV‐1‐infected subjects stimulates broad functional CD4+ T cell responses
inferredcites →https://doi.org/10.1007/bf01641272openalex-snapshot
Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA
inferredcites →https://doi.org/10.1016/j.amjcard.2005.01.061openalex-snapshot
Comparison of Clinical Presentation of Acute Myocarditis Following Smallpox Vaccination to Acute Coronary Syndromes in Patients <40 Years of Age⁎⁎The opinions and research contained herein are the private ones of the investigators and are not to be considered as official or reflecting the views of…
inferredcites →https://doi.org/10.1016/j.amjmed.2008.07.025openalex-snapshot
Electrocardiography Screening for Cardiotoxicity after Modified Vaccinia Ankara Vaccination
inferredcites →https://doi.org/10.1016/j.jacc.2003.11.053openalex-snapshot
Smallpox vaccination and myopericarditis: a clinical review
inferredcites →https://doi.org/10.1016/j.jacc.2004.05.004openalex-snapshot
Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination11The views expressed in this study are those of the authors and do not reflect the official policy or position of the U.S. government.
inferredcites →https://doi.org/10.1016/j.vaccine.2005.11.022openalex-snapshot
Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine
inferredcites →https://doi.org/10.1016/j.vaccine.2007.10.017openalex-snapshot
Clinical and immunologic responses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® challenge
inferredcites →https://doi.org/10.1016/j.vaccine.2009.05.095openalex-snapshot
Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain
inferredcites →https://doi.org/10.1016/j.vaccine.2009.11.030openalex-snapshot
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE®
inferredcites →https://doi.org/10.1038/nature02331openalex-snapshot
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox
inferredcites →https://doi.org/10.1038/nm1261openalex-snapshot
Smallpox vaccine–induced antibodies are necessary and sufficient for protection against monkeypox virus
inferredcites →https://doi.org/10.1038/nm1273openalex-snapshot
Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox
inferredcites →https://doi.org/10.1055/s-0028-1108143openalex-snapshot
MVA-Stufenimpfung gegen Pocken
inferredcites →https://doi.org/10.1056/nejm196701192760301openalex-snapshot
Complications of Smallpox Vaccination
inferredcites →https://doi.org/10.1056/nejm196911272812201openalex-snapshot
Complications of Smallpox Vaccination, 1968
inferredcites →https://doi.org/10.1056/nejm198011273032204openalex-snapshot
The Confirmation and Maintenance of Smallpox Eradication
inferredcites →https://doi.org/10.1056/nejm198703123161106openalex-snapshot
Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) Disease
inferredcites →https://doi.org/10.1073/pnas.0804985105openalex-snapshot
Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus
inferredcites →https://doi.org/10.1086/587668openalex-snapshot
Severe Eczema Vaccinatum in a Household Contact of a Smallpox Vaccinee
inferredcites →https://doi.org/10.1093/aje/kwh269openalex-snapshot
Myopericarditis following Smallpox Vaccination
inferredcites →https://doi.org/10.1093/infdis/122.4.303openalex-snapshot
Complications of Smallpox Vaccination, 1968: Results of Ten Statewide Surveys
inferredcites →https://doi.org/10.1099/vir.0.010553-0openalex-snapshot
Evaluation of smallpox vaccines using variola neutralization
inferredcites →https://doi.org/10.1128/jvi.02061-06openalex-snapshot
Induction of Natural Killer Cell Responses by Ectromelia Virus Controls Infection
inferredcites →https://doi.org/10.1128/jvi.79.12.7845-7851.2005openalex-snapshot
Modified Vaccinia Virus Ankara Protects Macaques against Respiratory Challenge with Monkeypox Virus
inferredcites →https://doi.org/10.1128/jvi.80.10.4717-4728.2006openalex-snapshot
Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8+T-Cell Epitopes
inferredcites →https://doi.org/10.1172/jci33940openalex-snapshot
Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection
inferredcites →https://doi.org/10.1177/135965350501000212openalex-snapshot
Therapeutic Vaccination of HIV-1-Infected Patients on Haart with a Recombinant HIV-1 Nef -Expressing Mva: Safety, Immunogenicity and Influence on Viral Load during Treatment Interruption
inferredcites →https://doi.org/10.1586/14760584.8.1.13openalex-snapshot
IMVAMUNE ® : modified vaccinia Ankara strain as an attenuated smallpox vaccine
inferredcites →https://doi.org/10.2174/1568005033481123openalex-snapshot
Vaccinia Vectors as Candidate Vaccines: The Development of Modified Vaccinia Virus Ankara for Antigen Delivery
inferredcites →https://doi.org/10.4049/jimmunol.171.10.4969openalex-snapshot
Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4107499openalex-extracted
A Randomized Phase 3 Trial to Assess the Immunogenicity and Safety of 3 Consecutively Produced Lots of Freeze-Dried MVA‑BN® Vaccine in Healthy Adults
inferred← citeshttps://doi.org/10.2139/ssrn.4138312openalex-extracted
Monkeypox 2022 Identify-Isolate-Inform (3I): A Tool for Frontline Clinicians For a Zoonosis with Escalating Human Community Transmission
inferred← citeshttps://doi.org/10.2139/ssrn.4572849openalex-extracted
Immunogenicity and Reactogenicity of Modified Vaccinia Ankara Pre-Exposure Vaccination Against Mpox According to Previous Smallpox Vaccine Exposure
inferred← citeshttps://doi.org/10.2139/ssrn.4802678openalex-extracted
The Safety, Immunogenicity, and Optimal Dosing of an MVA-Based Vaccine Against MERS Coronavirus in Healthy Adults: A Phase 1b, Randomised, Placebo-Controlled, Double-Blind Clinical Trial
inferred← citeshttps://doi.org/10.1002/hsr2.798openalex-snapshot
Repositioning potentials of smallpox vaccines and antiviral agents in monkeypox outbreak: A rapid review on comparative benefits and risks
inferred← citeshttps://doi.org/10.1002/jmv.28644openalex-snapshot
Inborn errors of immunity and worries during the monkeypox outbreak
inferred← citeshttps://doi.org/10.1002/jmv.29134openalex-snapshot
Development of a novel serological assay for the detection of mpox infection in vaccinated populations
inferred← citeshttps://doi.org/10.1002/mco2.70399openalex-snapshot
Impaired Cellular Immunity and Cross‐Reactive Humoral Responses to Mpox Virus in HIV‐Infected Individuals Vaccinated with Vaccinia Virus Tiantan Strain
inferred← citeshttps://doi.org/10.1002/med.22085openalex-snapshot
An overview of the progress made in research into the Mpox virus
inferred← citeshttps://doi.org/10.1002/rmv.2522openalex-snapshot
Breakthrough infection and reinfection in patients with mpox
inferred← citeshttps://doi.org/10.1007/s11030-023-10767-8openalex-snapshot
Exploring Monkeypox: prospects for therapeutics through computational-aided drug discovery
inferred← citeshttps://doi.org/10.1007/s11904-025-00731-6openalex-snapshot
Update on Vaccination Recommendations for Adults with HIV
inferred← citeshttps://doi.org/10.1007/s40121-017-0165-yopenalex-snapshot
Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II
inferred← citeshttps://doi.org/10.1007/s40506-022-00260-5openalex-snapshot
Mpox: Special Considerations in the Immunocompromised Host
inferred← citeshttps://doi.org/10.1016/b978-0-323-35761-6.00054-7openalex-snapshot
Smallpox and Vaccinia
inferred← citeshttps://doi.org/10.1016/b978-0-323-79058-1.00055-4openalex-snapshot
Smallpox and Vaccinia
inferred← citeshttps://doi.org/10.1016/b978-0-323-79058-1.00210-3openalex-snapshot
Vaccines to Prevent Mpox
inferred← citeshttps://doi.org/10.1016/j.antiviral.2018.11.004openalex-snapshot
Vaccinating against monkeypox in the Democratic Republic of the Congo
inferred← citeshttps://doi.org/10.1016/j.biologicals.2026.101886openalex-snapshot
Alternative approaches to phase III clinical trials for vaccine efficacy and licensure: the role of real-world evidence – a meeting report
inferred← citeshttps://doi.org/10.1016/j.ebiom.2022.104424openalex-snapshot
The land-scape of immune response to monkeypox virus
inferred← citeshttps://doi.org/10.1016/j.eclinm.2023.102420openalex-snapshot
Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study
inferred← citeshttps://doi.org/10.1016/j.idnow.2022.09.013openalex-snapshot
Proposal of the French HIV Society on the CD4 threshold below which patients living with HIV who wish to be vaccinated against Monkeypox should receive a 3-dose regimen
inferred← citeshttps://doi.org/10.1016/j.jcyt.2020.04.098openalex-snapshot
Identification of protective T-cell antigens for smallpox vaccines
inferred← citeshttps://doi.org/10.1016/j.jfma.2023.10.019openalex-snapshot
Update on the M-pox virus and safety measures taken against it globally
inferred← citeshttps://doi.org/10.1016/j.jinf.2025.106602openalex-snapshot
Humoral and T-cell responses following MVA-BN booster vaccination against mpox virus clades Ib and IIb
inferred← citeshttps://doi.org/10.1016/j.jmb.2023.168173openalex-snapshot
Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases
inferred← citeshttps://doi.org/10.1016/j.onehlt.2022.100410openalex-snapshot
Monkeypox 2022 Identify-Isolate-Inform: A 3I Tool for frontline clinicians for a zoonosis with escalating human community transmission
inferred← citeshttps://doi.org/10.1016/j.tmaid.2023.102636openalex-snapshot
Addressing the resurgence of global monkeypox (Mpox) through advanced drug delivery platforms
inferred← citeshttps://doi.org/10.1016/j.vaccine.2014.02.043openalex-snapshot
Phase II randomized, double-blinded comparison of a single high dose (5×108 TCID50) of modified vaccinia Ankara compared to a standard dose (1×108 TCID50) in healthy vaccinia-naïve individuals
inferred← citeshttps://doi.org/10.1016/j.vaccine.2014.08.022openalex-snapshot
Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis
inferred← citeshttps://doi.org/10.1016/j.vaccine.2015.06.075openalex-snapshot
Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects
inferred← citeshttps://doi.org/10.1016/j.vaccine.2017.02.032openalex-snapshot
Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial
inferred← citeshttps://doi.org/10.1016/j.vaccine.2018.06.064openalex-snapshot
Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses
inferred← citeshttps://doi.org/10.1016/j.vaccine.2020.01.055openalex-snapshot
Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial
inferred← citeshttps://doi.org/10.1016/j.vaccine.2020.01.058openalex-snapshot
A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS
inferred← citeshttps://doi.org/10.1016/j.vaccine.2020.08.050openalex-snapshot
The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform
inferred← citeshttps://doi.org/10.1016/j.vaccine.2022.10.056openalex-snapshot
A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN® vaccine in healthy adults
inferred← citeshttps://doi.org/10.1016/j.vaccine.2022.10.078openalex-snapshot
Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of Congo
inferred← citeshttps://doi.org/10.1016/j.vaccine.2023.12.068openalex-snapshot
Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study
inferred← citeshttps://doi.org/10.1016/j.vaccine.2024.03.011openalex-snapshot
Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial
inferred← citeshttps://doi.org/10.1016/j.vaccine.2024.05.017openalex-snapshot
Serologic responses to the MVA-based JYNNEOS mpox vaccine in a cohort of participants from the District of Columbia (D.C.)
inferred← citeshttps://doi.org/10.1016/j.vaccine.2024.126521openalex-snapshot
A Brighton collaboration standardized template with key considerations for a benefit/risk assessment for a viral vector vaccine based on a non-replicating modified vaccinia virus Ankara viral vector
inferred← citeshttps://doi.org/10.1016/j.vaccine.2025.127959openalex-snapshot
Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination
inferred← citeshttps://doi.org/10.1016/s1473-3099(25)00779-0openalex-snapshot
Safety of MVA-BN vaccine in health-care personnel in DR Congo: a prospective cohort study
inferred← citeshttps://doi.org/10.1016/s1473-3099(26)00001-0openalex-snapshot
Immunogenicity and safety of MVA-BN vaccine administered 5 years after a two-dose primary series in DR Congo: a prospective cohort study
inferred← citeshttps://doi.org/10.1017/dmp.2020.478openalex-snapshot
Myopericarditis Associated With Smallpox Vaccination Among US Army Personnel – Fort Hood, Texas, 2018
inferred← citeshttps://doi.org/10.1017/s0950268817002795openalex-snapshot
Does smallpox vaccination modify HIV disease progression among ART-naive people living with HIV in Africa?
inferred← citeshttps://doi.org/10.1038/s41392-022-01215-4openalex-snapshot
Monkeypox: epidemiology, pathogenesis, treatment and prevention
inferred← citeshttps://doi.org/10.1038/s41467-023-43299-8openalex-snapshot
Quantitative proteomics defines mechanisms of antiviral defence and cell death during modified vaccinia Ankara infection
inferred← citeshttps://doi.org/10.1038/s41541-025-01094-0openalex-snapshot
Efficacy of emergency maternal MVA-ZIKV vaccination in a rapid challenge model of lethal Zika infection
inferred← citeshttps://doi.org/10.1056/nejmoa1817307openalex-snapshot
Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
inferred← citeshttps://doi.org/10.1073/pnas.2202069119openalex-snapshot
Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection
inferred← citeshttps://doi.org/10.1080/07391102.2018.1554510openalex-snapshot
Design of inhibitors of thymidylate kinase from Variola virus as new selective drugs against smallpox: part II
inferred← citeshttps://doi.org/10.1080/14712598.2018.1404572openalex-snapshot
From bench to almost bedside: the long road to a licensed Ebola virus vaccine
inferred← citeshttps://doi.org/10.1080/14760584.2024.2397006openalex-snapshot
Vaccines against mpox: MVA-BN and LC16m8
inferred← citeshttps://doi.org/10.1080/14760584.2026.2708197openalex-snapshot
ACAM2000 vaccine safety and immunogenicity considerations for smallpox and mpox
inferred← citeshttps://doi.org/10.1080/21645515.2023.2242219openalex-snapshot
An open-label, non-randomized study investigating the safety and efficacy of smallpox vaccine, LC16, as post-exposure prophylaxis for mpox
inferred← citeshttps://doi.org/10.1080/22221751.2022.2132882openalex-snapshot
Comprehensive literature review of monkeypox
inferred← citeshttps://doi.org/10.1089/aid.2023.0034openalex-snapshot
Human Mpox in People Living with HIV: Epidemiologic and Clinical Perspectives from Nigeria
inferred← citeshttps://doi.org/10.1093/infdis/jiac455openalex-snapshot
One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines
inferred← citeshttps://doi.org/10.1093/infdis/jiad052openalex-snapshot
Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
inferred← citeshttps://doi.org/10.1093/infdis/jiae138openalex-snapshot
Mpox-Specific Immune Responses Elicited by Vaccination or Infection in People With HIV
inferred← citeshttps://doi.org/10.1093/infdis/jit105openalex-snapshot
Safety and Immunogenicity of Modified Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial
inferred← citeshttps://doi.org/10.1093/ofid/ofaf536openalex-snapshot
Antibody Responses are Sustained 2 Years Post-Mpox Infection but not Following Modified Vaccinia Ankara–Bavarian Nordic Vaccination
inferred← citeshttps://doi.org/10.1093/ofid/ofv040openalex-snapshot
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial
inferred← citeshttps://doi.org/10.1097/qad.0000000000003733openalex-snapshot
Viral blips and virologic failures following mpox vaccination with MVA-BN among people with HIV
inferred← citeshttps://doi.org/10.1097/qco.0000000000000994openalex-snapshot
Mpox in people living with HIV
inferred← citeshttps://doi.org/10.1101/2022.09.07.22279689openalex-snapshot
Single and 2-dose vaccinations with MVA-BN ® induce durable B cell memory responses in healthy volunteers that are comparable to older generation replicating smallpox vaccines
inferred← citeshttps://doi.org/10.1101/2024.06.06.24308551openalex-snapshot
Safety and Effectiveness of LC16m8 for Pre-Exposure Prophylaxis against mpox in a High-Risk Population: An Open-Label Randomized Trial
inferred← citeshttps://doi.org/10.1101/2025.06.06.25329130openalex-snapshot
MVA-BN third-dose 5 years after primary; Democratic Republic of the Congo
inferred← citeshttps://doi.org/10.1101/2025.06.11.25328898openalex-snapshot
Safety of MVA-BN in Healthcare Personnel, Democratic Republic of the Congo
inferred← citeshttps://doi.org/10.1111/hiv.12424openalex-snapshot
B ritish HIV A ssociation Guidelines on the Use of Vaccines in HIV ‐Positive Adults 2015
inferred← citeshttps://doi.org/10.1111/hiv.13661openalex-snapshot
Mpox in people with HIV : A narrative review
inferred← citeshttps://doi.org/10.1128/jvi.00253-25openalex-snapshot
The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response
inferred← citeshttps://doi.org/10.1128/jvi.00614-15openalex-snapshot
Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein
inferred← citeshttps://doi.org/10.1128/jvi.01154-19openalex-snapshot
Modified Vaccinia Virus Ankara Can Induce Optimal CD8 + T Cell Responses to Directly Primed Antigens Depending on Vaccine Design
inferred← citeshttps://doi.org/10.1136/bmjopen-2026-120064openalex-snapshot
Examining the immune response of participants receiving Modified Vaccinia Ankara vaccine in Africa (MpoxVax AFRIVAC): a prospective cohort study – protocol
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-19-0183openalex-snapshot
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules
inferred← citeshttps://doi.org/10.1172/jci167632openalex-snapshot
Vaxxing to elimination: smallpox vaccines as tools to fight mpox
inferred← citeshttps://doi.org/10.1177/153567601502000102openalex-snapshot
Vaccinia Virus—Laboratory Tool with a Risk of Laboratory-Acquired Infection
inferred← citeshttps://doi.org/10.1186/1745-6215-15-68openalex-snapshot
Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design
inferred← citeshttps://doi.org/10.1186/s12889-024-19260-9openalex-snapshot
Willingness to receive mpox vaccine among men who have sex with men: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1186/s12982-025-01174-5openalex-snapshot
Appraising the current landscape of reviews on mpox vaccination: a rapid evidence map
inferred← citeshttps://doi.org/10.1186/s40779-025-00660-wopenalex-snapshot
Emerging strategies for monkeypox: antigen and antibody applications in diagnostics, vaccines, and treatments
inferred← citeshttps://doi.org/10.12659/ajcr.941006openalex-snapshot
The Reemerging Condition of Vaccinia: A Case Report and Brief Review of Monkeypox and Vaccinia Vaccines
inferred← citeshttps://doi.org/10.1371/journal.pone.0073511openalex-snapshot
A Novel Naturally Occurring Tandem Promoter in Modified Vaccinia Virus Ankara Drives Very Early Gene Expression and Potent Immune Responses
inferred← citeshttps://doi.org/10.1371/journal.pone.0122653openalex-snapshot
Cardiac Safety of Modified Vaccinia Ankara for Vaccination against Smallpox in a Young, Healthy Study Population
inferred← citeshttps://doi.org/10.1371/journal.pone.0138348openalex-snapshot
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis
inferred← citeshttps://doi.org/10.1371/journal.pone.0157335openalex-snapshot
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects
inferred← citeshttps://doi.org/10.1371/journal.pone.0195897openalex-snapshot
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial
inferred← citeshttps://doi.org/10.1371/journal.ppat.1003756openalex-snapshot
An Increasing Danger of Zoonotic Orthopoxvirus Infections
inferred← citeshttps://doi.org/10.1371/journal.ppat.1004108openalex-snapshot
Are We There Yet? The Smallpox Research Agenda Using Variola Virus
inferred← citeshttps://doi.org/10.15585/mmwr.mm7132e4openalex-snapshot
Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection — United States, August 2022
inferred← citeshttps://doi.org/10.1590/0102-311xpt006624openalex-snapshot
Estudo descritivo dos eventos supostamente atribuíveis à vacinação contra a mpox no Brasil em 2023
inferred← citeshttps://doi.org/10.21055/0370-1069-2021-3-13-22openalex-snapshot
The Results of Clinical Trials of Recombinant Vaccine Virus, MVA Strain, Expressing Genes of Human Immunodeficiency Virus
inferred← citeshttps://doi.org/10.21055/0370-1069-2023-4-24-31openalex-snapshot
Comparison of the Efficacy of Different Schemes for Using Recombinant Vector Vaccines against Ebola Fever, Based on Vaccinia Virus, MVA Strain
inferred← citeshttps://doi.org/10.21055/0370-1069-2025-4-6-16openalex-snapshot
Analysis of the Experience of Improving the Safety of Anti-Smallpox Vaccines
inferred← citeshttps://doi.org/10.2174/1871526523666230427144755openalex-snapshot
Human Monkeypox Virus: Current State of Knowledge and Implications for the Imminent Days
inferred← citeshttps://doi.org/10.2196/46955openalex-snapshot
Efficacy and Safety of the Smallpox Vaccine for Postexposure Prophylaxis in Monkeypox: Protocol for an Open-Labeled, Single-Armed Study
inferred← citeshttps://doi.org/10.30895/2221-996x-2023-23-1-26-41openalex-snapshot
Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
inferred← citeshttps://doi.org/10.3389/fimmu.2020.598847openalex-snapshot
A Monovalent and Trivalent MVA-Based Vaccine Completely Protects Mice Against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenge
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1203410openalex-snapshot
Recombinant proteins A29L, M1R, A35R, and B6R vaccination protects mice from mpox virus challenge
inferred← citeshttps://doi.org/10.3389/fpubh.2022.997637openalex-snapshot
Knowledge and vaccination acceptance toward the human monkeypox among men who have sex with men in China
inferred← citeshttps://doi.org/10.3390/pathogens11080924openalex-snapshot
Monkeypox and Its Possible Sexual Transmission: Where Are We Now with Its Evidence?
inferred← citeshttps://doi.org/10.3390/pathogens14121293openalex-snapshot
Immune Responses and Protective Efficacy of Nanoemulsion-Adjuvanted Monkeypox Virus Recombinant Vaccines Against Lethal Challenge in Mice
inferred← citeshttps://doi.org/10.3390/tropicalmed1010008openalex-snapshot
Human Monkeypox: Current State of Knowledge and Implications for the Future
inferred← citeshttps://doi.org/10.3390/v15091844openalex-snapshot
Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus
inferred← citeshttps://doi.org/10.3390/v17121526openalex-snapshot
Mpox: Exploring Epidemiology, Disease Outcomes, and Preventative Vaccination Among People with HIV During the Ongoing Outbreaks
inferred← citeshttps://doi.org/10.3390/vaccines10091419openalex-snapshot
Preventing the Next Pandemic: Is Live Vaccine Efficacious against Monkeypox, or Is There a Need for Killed Virus and mRNA Vaccines?
inferred← citeshttps://doi.org/10.3390/vaccines10122091openalex-snapshot
Disease History, Pathogenesis, Diagnostics, and Therapeutics for Human Monkeypox Disease: A Comprehensive Review
inferred← citeshttps://doi.org/10.3390/vaccines11030528openalex-snapshot
Perception of and Vaccine Readiness towards Mpox among Men Who Have Sex with Men Living with HIV in China: A Cross-Sectional Study
inferred← citeshttps://doi.org/10.3390/vaccines11050896openalex-snapshot
Living with HIV and Getting Vaccinated: A Narrative Review
inferred← citeshttps://doi.org/10.3390/vaccines11091410openalex-snapshot
Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.3390/vaccines11111708openalex-snapshot
Systematic Review on the Efficacy, Effectiveness, Safety, and Immunogenicity of Monkeypox Vaccine
inferred← citeshttps://doi.org/10.3390/vaccines12010052openalex-snapshot
Protective MVA-ST Vaccination Robustly Activates T Cells and Antibodies in an Aged-Hamster Model for COVID-19
inferred← citeshttps://doi.org/10.3390/vaccines13090930openalex-snapshot
Immune Response to MVA-BN Vaccination for Mpox: Current Evidence and Future Directions
inferred← citeshttps://doi.org/10.36233/0372-9311-102openalex-snapshot
Using the vaccinia virus MVA strain for developing recombinant vector vaccines against current arboviral infections
inferred← citeshttps://doi.org/10.3917/rbm.382.0055openalex-snapshot
L’émergence de la variole du singe
inferred← citeshttps://doi.org/10.4049/jimmunol.1301161openalex-snapshot
Protection against Tuberculosis with Homologous or Heterologous Protein/Vector Vaccine Approaches Is Not Dependent on CD8+ T Cells
inferred← citeshttps://doi.org/10.53846/goediss-6818openalex-snapshot
Pathogenesis of orthopoxvirus (OPXV) infection in common CM and identification of immune correlates after vaccination with differently attenuated vaccines
inferred← citeshttps://doi.org/10.6084/m9.figshare.26749235openalex-snapshot
Additional file 1 of Willingness to receive mpox vaccine among men who have sex with men: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.6084/m9.figshare.26749238openalex-snapshot
Additional file 2 of Willingness to receive mpox vaccine among men who have sex with men: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.6084/m9.figshare.26749241openalex-snapshot
Additional file 3 of Willingness to receive mpox vaccine among men who have sex with men: a systematic review and meta-analysis
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.